Latest News

Final analysis from Phase 3 TITAN study demonstrated ERLEADA® provided statistically significant overall survival benefit and consistent safety profile in patients with advanced prostate cancer, regardless of extent of disease San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the final analysis of the Phase 3 TITAN study, which […]

ASCO Perspective “This study suggests that reduced PSA screening may come at the cost of more men presenting with metastatic prostate cancer. Patients should discuss the risks and benefits associated with PSA screening with their doctor to identify the best approach for them,” said Robert Dreicer, MD, MS, MACP, FASCO, ASCO expert in genitourinary cancers.

ASCO Perspective “Even with the current standard of care — surgery with or without pre-surgery chemotherapy —muscle-invasive urothelial carcinoma has a high risk of recurring. These new findings show that treating patients at highest risk of recurrence with an immunotherapy after surgery can help extend the time until the disease returns,” said Robert Dreicer, MD, […]

Key Points Question: Is magnetic resonance imaging (MRI) with targeted biopsy only non-inferior to systematic biopsy for the diagnosis of clinically significant prostate cancer (PCa)? Findings: In this prospective phase 3 randomized clinical trial of 453 men, clinically significant cancer was found in 35% vs 30% in the MRI and systematic biopsy arms, respectively, which […]

San Francisco, CA (UroToday.com) — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, announced presentations on Axumin® (fluciclovine F 18) at the upcoming ASCO 2021 Genitourinary Cancers Symposium (ASCO GU), from February 11 to 13, 2021, to be held in a virtual format. Details of selected […]

Phase III study ARANOTE to be initiated in metastatic hormone-sensitive prostate cancer (mHSPC) assessing the androgen receptor inhibitor (ARi) in combination with standard androgen deprivation therapy (ADT) Start of patient enrollment expected by the end of Q1 2021 Study adds to the robust development program for NUBEQA, exploring an opportunity to help even more patients […]

Robot-assisted laparoscopic radical prostatectomy (RARP) is becoming the standard treatment procedure for localized prostate cancer. The main complications associated with RARP include urinary incontinence and sexual dysfunction.

Objective: To evaluate the safety and effectiveness of laparoscopic sacrocolpopexy (LSC)/laparoscopic sacrohysteropexy (LSH) at 1-year follow-up for female pelvic-organ prolapse (POP). Patients and methods: In all, 52 patients were included and underwent LSC/LSH in the Eldemerdash Hospital, Ain Shams University, Cairo, Egypt.

Background: The inability to remove an indwelling urethral catheter in a postrobot-assisted laparoscopic radical prostatectomy (RALP) patient constitutes a serious problem to the urologist.

Ureteric ectopia is a pediatric urinary incontinence cause in girls. It is traditionally managed through hemi-nephrectomy or uretero-ureterostomy, which have the potential for complications including anastomotic stricture, leak, bleeding, and de-vascularization of the functioning renal moiety.